


<b>CERTIFICATE OF MAILING BY FIRST CLASS MAIL (37 CFR 1.8)</b> Applicant(s): Shcherbakova et al.			Docket No. 50821/15	
Application No. 10/551,920	Filing Date October 3, 2005	Examiner Not Assigned	Customer No. 32642	Group Art Unit
Invention: <b>METHODS FOR PREPARING 2,3,5,6-SUBSTITUTED 3H-PYRIMIDIN-4-ONES</b>				



I hereby certify that this Information Disclosure Statement (including the items listed below)

*(Identify type of correspondence)*


is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

FEB. 9, 2006

*(Date)*

**Kevin B. Laurence**

*(Typed or Printed Name of Person Mailing Correspondence)*



*(Signature of Person Mailing Correspondence)*

**Note: Each paper must have its own certificate of mailing.**

Transmitted: Information Disclosure Statement (3 pgs.)  
 PTO-Form 1449 listing one (1) references (1 pg.)  
 Transmittal for Information Disclosure Statement (2 pgs.)  
 Certificate of Mailing by First Class Mail (1 pg.)  
 Postcard

<b>TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT</b> (Under 37 CFR 1.97(b) or 1.97(c))					Docket No. 50821/15	
In Re Application Of: Shcherbakova et al.						
Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.	
10/551,920	October 3, 2005	Not Assigned	32642	32642		
Title: <b>METHODS FOR PREPARING 2,3,5,6-SUBSTITUTED 3H-PYRIMIDIN-4-ONES</b>						
Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450  <b>37 CFR 1.97(b)</b>  1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.  <b>37 CFR 1.97(c)</b>  2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:  <div style="margin-left: 40px;"> <input type="checkbox"/> the statement specified in 37 CFR 1.97(e);   <div style="text-align: center;">OR</div> <input type="checkbox"/> the fee set forth in 37 CFR 1.17(p).         </div>						

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**

(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.

50821/15

In Re Application of: Shcherbakova et al.

FEB 13, 2006

Application No.

10/551,920

Filing Date

October 3, 2005

Examiner

Not Assigned

Customer No.

32642

Group Art Unit

32642

Confirmation No.

Title: METHODS FOR PREPARING 2,3,5,6-SUBSTITUTED 3H-PYRIMIDIN-4-ONES

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 50-2375 as described below.
- ☐ Charge the amount of \_\_\_\_\_
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

**Certificate of Mailing by First Class Mail**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

(Date)

Signature of Person Mailing Correspondence

Typed or Printed Name of Person Mailing Certificate

\*This certificate may only be used if paying by deposit account.

*Kevin B. Laurence*  
Signature

Dated:

FEB 9, 2006

Kevin B. Laurence  
Registration No. 38,219  
Stoel Rives LLP  
One Utah Center  
201 South Main Street, Suite 1100  
Salt Lake City, UT 84111  
Telephone: 801-578-6932  
Facsimile: 801-578-6999

CC:

PATENT APPLICATION  
Docket No.: 50821/15

2. ☐ The Examiner's attention is directed to the enclosed copy of copending U.S. Patent Application No. \_\_\_\_\_, filed \_\_\_\_\_, for \_\_\_\_\_, which is cited in this application.
3. This information disclosure statement is being submitted (check box a., b., or c.):
- a. ☒ Within three months of the filing date of a national application or entry of the national stage in an international application; or before the mailing of a first Office action on the merits; or before the mailing of a first Office action after the filing of a request for continued examination under 37 CFR 1.114. (No statement under 37 CFR 1.97(e) is required.); or
- b. ☐ After the period set forth in paragraph 3a, but before the mailing date of either a final action, a notice of allowance, or an action that otherwise closes prosecution in the application. (Check box i. or ii.)
- i. ☐ A \$180.00 information disclosure statement submission fee set forth in 37 CFR 1.17(p) is enclosed, or
- ii. ☐ A statement specified by 37 CFR 1.97(e) is set forth below; or
- c. ☐ After the mailing date of a final action or notice of allowance and on or before payment of the issue fee. A statement specified by 37 CFR 1.97(e) is set forth below. Enclosed is a \$180.00 information disclosure statement processing fee set forth in 37 CFR 1.17(p).
4. If a statement specified by 37 CFR 1.97(e) is required, the attorney or agent signing below hereby states that:
- ☐ each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or
- ☐ no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement.

5. ☐ A concise explanation of the relevance of each document not in the English language and/or selected documents in the English language is included.

DATED this 9<sup>TH</sup> day of FEBRUARY, 2006.


Respectfully submitted,



Kevin B. Laurence  
Registration No. 38,219

Stoel Rives LLP  
One Utah Center  
201 South Main Street, Suite 1100  
Salt Lake City, UT 84111  
Telephone: 801-578-6932  
Facsimile: 801-578-6999

**CUSTOMER NO. 32642**



# INFORMATION DISCLOSURE CITATION

FORM PTO-1449  
(REV. 7-80)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.  
50821/15

APPLICATION NO.  
10/551,920

TITLE: METHODS FOR PREPARING 2,3,5,6-SUBSTITUTED  
3H-PYRIMIDIN-4-ONES

APPLICANT - Shcherbakova et al.

CUSTOMER NO.: 32642

FILING DATE-

GROUP-

October 3, 2005

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

1

Jeong, An Efficient Synthesis of 3-Substituted 3H-Pyrimidin-4ones, Organic Letters, Vol 6, No. 6, 2004  
(pp.1013-1016)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.